

All Databases

PubMed

Nucleotide

Protein

Genome

Structure

OMIM

PMC

Journals

Books

Search PubMed

for Fukuda and platelet aggregation

Go

Clear

Save Search

☒ Limits

Preview/Index

History

Clipboard

Details

Limits: Publication Date to 2000/10/4

Display Summary

Show 20

Sort by

Send to

About Entrez

Text Version

All: 24

Review: 0



Entrez PubMed

Items 1 - 20 of 24

Page 1

of 2 Next

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

Special Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

- ☐ 1: [Tanaka T, Fukuda Y, Fukuda Y, Higashino R, Ito S, Takei M, Tamaki H, Kurimoto T, Suzuki Y.](#)

Related Articles, Links



Z-335, a thromboxane A2 receptor antagonist, suppresses the progression of arachidonic acid-induced hind limb gangrene in rats.

Biol Pharm Bull. 1999 Dec;22(12):1382-4.

PMID: 10746175 [PubMed - indexed for MEDLINE]

- ☐ 2: [Fukuda K, Mizuno H, Atoda H, Morita T.](#)

Related Articles, Links



Crystal structure of flavocetin-A, a platelet glycoprotein Ib-binding protein, reveals a novel cyclic tetramer of C-type lectin-like heterodimers.

Biochemistry. 2000 Feb 29;39(8):1915-23.

PMID: 10684640 [PubMed - indexed for MEDLINE]

- ☐ 3: [Tanaka T, Fukuda Y, Higashino R, Sato R, Nomura Y, Fukuda Y, Ito S, Takei M, Kurimoto T, Tamaki H.](#)

Related Articles, Links



Antiplatelet effect of Z-335, a new orally active and long-lasting thromboxane receptor antagonist.

Eur J Pharmacol. 1998 Sep 11;357(1):53-60.

PMID: 9788773 [PubMed - indexed for MEDLINE]

- ☐ 4: [Ichinohe T, Fukuda K, Kaneko Y.](#)

Related Articles, Links



Epinephrine at doses used in dentistry deteriorates platelet retention rate.

Anesth Prog. 1997 Spring;44(2):59-63.

PMID: 9481962 [PubMed - indexed for MEDLINE]

- ☐ 5: [Fukuda K, Ozaki Y, Satoh K, Kume S, Tawata M, Onaya T, Sakurada K, Seto M, Sasaki Y.](#)

Related Articles, Links



Phosphorylation of myosin light chain in resting platelets from NIDDM patients is enhanced: correlation with spontaneous aggregation.

Diabetes. 1997 Mar;46(3):488-93.

PMID: 9032107 [PubMed - indexed for MEDLINE]

- ☐ 6: [Naganawa R, Iwata N, Ishikawa K, Fukuda H, Fujino T, Suzuki A.](#)

Related Articles, Links











Inhibition of microbial growth by ajoene, a sulfur-containing compound derived from garlic.

Appl Environ Microbiol. 1996 Nov;62(11):4238-42.







PMID: 8900018 [PubMed - indexed for MEDLINE]

- ☐ 7: [Kannan K, Divers SG, Lurie AA, Chervenak R, Fukuda M, Holcombe RF.](#)

Related Articles, Links


-  Cell surface expression of lysosome-associated membrane protein-2 (lamp2) and CD63 as markers of in vivo platelet activation in malignancy. Eur J Haematol. 1995 Sep;55(3):145-51. PMID: 7672086 [PubMed - indexed for MEDLINE]
- ☐ **8:** [Fukuda T, Numao T, Akutsu I, Makino S.](#) [Related Articles, Links](#)
-  Platelet-activating factor (PAF)-induced chemotaxis and PAF binding to human eosinophils. J Lipid Mediat. 1992 Jun-Jul;5(2):145-9. PMID: 1525356 [PubMed - indexed for MEDLINE]
- ☐ **9:** [Ohta F, Kawahara M, Sekimoto H, Fukuda M, Takaya M, Yamasaki T, Moritake K.](#) [Related Articles, Links](#)
-  [Pathophysiological study of corona radiata infarcts by clinically available diagnostic methods] No To Shinkei. 1991 Feb;43(2):155-61. Japanese. PMID: 1873085 [PubMed - indexed for MEDLINE]
- ☐ **10:** [Yasuba H, Kino T, Fukuda K, Matsui Y, Izumi T, Oshima S, Chihara J.](#) [Related Articles, Links](#)
-  [Platelet activation during exacerbation of bronchial asthma--thrombin induced ATP release from washed platelets and plasma beta-TG, PF4, beta-TG/PF4 ratio] Arerugi. 1988 Dec;37(12):1152-60. Japanese. No abstract available. PMID: 2977722 [PubMed - indexed for MEDLINE]
- ☐ **11:** [Nishimori T, Nishimura T, Kobayashi F, Nakano D, Fukuda Y, Sakonjyo H, Nakanishi J, Kimura A, Tsuji H, Higashio T, et al.](#) [Related Articles, Links](#)
-  [Effects of cadralazine on the respiration, circulation, kidney, autonomic nervous system, digestive system, blood and so on] Nippon Yakurigaku Zasshi. 1988 Apr;91(4):221-36. Japanese. PMID: 3391446 [PubMed - indexed for MEDLINE]
- ☐ **12:** [Saito T, Fukuda T, Tajima S, Sukamoto T, Yamashita A, Kanazawa T, Morimoto Y, Shimohara K, Nishimura N, Yokota K, et al.](#) [Related Articles, Links](#)
-  General pharmacology of 1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)benzimidazole difumarate. 2nd communication: Effects on the circulation and the other systems. Arzneimittelforschung. 1988 Feb;38(2):267-72. PMID: 2897196 [PubMed - indexed for MEDLINE]
- ☐ **13:** [Arisaka M, Arisaka O, Fukuda Y, Yamashiro Y.](#) [Related Articles, Links](#)
-  Prostaglandin metabolism in children with diabetes mellitus. I. Plasma prostaglandin E2, F2 alpha, TXB2, and serum fatty acid levels. J Pediatr Gastroenterol Nutr. 1986 Nov-Dec;5(6):878-82. PMID: 3467055 [PubMed - indexed for MEDLINE]
- ☐ **14:** [Tanaka K, Shibata N, Okamoto K, Matsusaka T, Fukuda H, Takagi M, Fujii N, Toya N, Onji T.](#) [Related Articles, Links](#)
-  Reorganization of myosin in surface-activated spreading platelets. J Ultrastruct Mol Struct Res. 1986 Oct-Dec;97(1-3):165-86. PMID: 3134496 [PubMed - indexed for MEDLINE]
- ☐ **15:** [Maeda H, Fukuda T, Tatsumi N.](#) [Related Articles, Links](#)

Changes in size distribution curve on the process of platelet aggregation

-  induced by various agents.  
Osaka City Med J. 1984 Dec;30(2):79-90. No abstract available.  
PMID: 6536914 [PubMed - indexed for MEDLINE]
- ☐ **16:** [Fukuda I.](#) [Related Articles, Links](#)
-  [The role of blood viscosity]  
Nippon Rinsho. 1983;41(2):306-14. Japanese. No abstract available.  
PMID: 6865007 [PubMed - indexed for MEDLINE]
- ☐ **17:** [Fukuda Y, Kuroiwa Y, Tabuchi H, Ohshige T, Sanada J, Minami Y, Takaoka S, Kataoka H, Furukawa S, Miyahara K, Nakamura K, Hashimoto S.](#) [Related Articles, Links](#)
-  A thrombotic tendency in patients with infective endocarditis.  
Jpn Circ J. 1982 May;46(5):460-7.  
PMID: 6210785 [PubMed - indexed for MEDLINE]
- ☐ **18:** [Tatsumi N, Wada Y, Fukuda T.](#) [Related Articles, Links](#)
-  Effect of phalloidin on platelet aggregation.  
Tohoku J Exp Med. 1980 Jul;131(3):221-5.  
PMID: 7414606 [PubMed - indexed for MEDLINE]
- ☐ **19:** [Yoshimura R, Asai H, Harihara S, Kamata T, Monna T, Yamamoto S, Fukuda T, Maeda H.](#) [Related Articles, Links](#)
-  Studies on hemorrhagic tendency in cirrhosis of the liver.  
Gastroenterol Jpn. 1979 Aug;14(4):353-65.  
PMID: 90631 [PubMed - indexed for MEDLINE]
- ☐ **20:** [Sato M, Ishizuka Y, Tanizawa H, Fukuda T, Yuizono T.](#) [Related Articles, Links](#)
-  [Pharmacological studies of 4-ethoxy-2-methyl-5-morpholino-3(2H)-pyridazinone (M73101). (3). General pharmacological actions (author's transl)]  
Nippon Yakurigaku Zasshi. 1979 Apr 20;75(3):291-307. Japanese.  
PMID: 317064 [PubMed - indexed for MEDLINE]

Items 1 - 20 of 24

Page 1 of 2

[Next](#)Display [Summary](#) Show 20 Sort by Send to[Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)[Department of Health & Human Services](#)[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Apr 18 2005 07:10:12

National  
Library  
of MedicineMy NC  
[Sign In] [Regis]

All Databases

PubMed

Nucleotide

Protein

Genome

Structure

OMIM

PMC

Journals

Book

Search PubMed

for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

Display Summary

Show 20

Sort by

Send to

About Entrez

Text Version

All: 253 Review: 18

Items 1 - 20 of 253

Page 1

of 13 Next

## Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

## PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

Special Queries

LinkOut

My NCBI (Cubby)

## Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

☐ 1: Fukuda K, Mizuno H, Atoda H, Morita T.

Related Articles, Links

**Crystal structure of flavocetin-A, a platelet glycoprotein Ib-binding protein, reveals a novel cyclic tetramer of C-type lectin-like heterodimers.**

Biochemistry. 2000 Feb 29;39(8):1915-23.

PMID: 10684640 [PubMed - indexed for MEDLINE]

☐ 2: Shin Y, Okuyama I, Hasegawa J, Morita T.

Related Articles, Links

**Molecular cloning of glycoprotein Ib-binding protein, flavocetin-A, which inhibits platelet aggregation.**

Thromb Res. 2000 Aug 1;99(3):239-47.

PMID: 10942790 [PubMed - indexed for MEDLINE]

☐ 3: Fukuda K, Mizuno H, Atoda H, Morita T.

Related Articles, Links

**Crystallization and preliminary x-ray studies of flavocetin-A, a platelet glycoprotein Ib-binding protein from the habu snake venom.**

Acta Crystallogr D Biol Crystallogr. 1999 Nov;55(11):1911-3.

PMID: 10531492 [PubMed - indexed for MEDLINE]

☐ 4: Andrews RK, Kroll MH, Ward CM, Rose JW, Scarborough RM, Smith AI, Lopez JA, Berndt MC.

Related Articles, Links

**Binding of a novel 50-kilodalton alboaggregin from Trimeresurus albolabris and related viper venom proteins to the platelet membrane glycoprotein Ib-IX-V complex. Effect on platelet aggregation and glycoprotein Ib-mediated platelet activation.**

Biochemistry. 1996 Sep 24;35(38):12629-39.

PMID: 8823201 [PubMed - indexed for MEDLINE]

☐ 5: Huang KF, Ko TP, Hung CC, Chu J, Wang AH, Chiou SH.

Related Articles, Links

**Crystal structure of a platelet-agglutinating factor isolated from the venom of Taiwan habu (Trimeresurus mucrosquamatus).**

Biochem J. 2004 Mar 1;378(Pt 2):399-407.

PMID: 14613481 [PubMed - indexed for MEDLINE]









☐ 6: Sakurai Y, Fujimura Y, Kokubo T, Imamura K, Kawasaki T, Handa M, Suzuki M, Matsui T, Titani K, Yoshioka A.







Related Articles, Links

**The cDNA cloning and molecular characterization of a snake venom platelet glycoprotein Ib-binding protein, mamushigin, from Agkistrodon halys blomhoffii venom.**

Thromb Haemost. 1998 Jun;79(6):1199-207.

PMID: 9657448 [PubMed - indexed for MEDLINE]

- ☐ **7:** [Mizuno H, Fujimoto Z, Koizumi M, Kano H, Atoda H, Morita T.](#) Related Articles, Links  
 Crystal structure of coagulation factor IX-binding protein from habu snake venom at 2.6 Å: implication of central loop swapping based on deletion in the linker region.  
J Mol Biol. 1999 May 28;289(1):103-12.  
PMID: 10339409 [PubMed - indexed for MEDLINE]
- ☐ **8:** [Murakami MT, Zela SP, Gava LM, Michelan-Duarte S, Cintra AC, Ami RK.](#) Related Articles, Links  
 Crystal structure of the platelet activator convulxin, a disulfide-linked alpha4beta4 cyclic tetramer from the venom of *Crotalus durissus terrificus*.  
Biochem Biophys Res Commun. 2003 Oct 17;310(2):478-82.  
PMID: 14521935 [PubMed - indexed for MEDLINE]
- ☐ **9:** [Wang WJ, Huang TF.](#) Related Articles, Links  
 A novel tetrameric venom protein, agglucetin from *Agkistrodon acutus*, acts as a glycoprotein Ib agonist.  
Thromb Haemost. 2001 Oct;86(4):1077-86.  
PMID: 11686327 [PubMed - indexed for MEDLINE]
- ☐ **10:** [De Luca M, Facey DA, Favaloro EJ, Hertzberg MS, Whisstock JC, McNally T, Andrews RK, Berndt MC.](#) Related Articles, Links  
 Structure and function of the von Willebrand factor A1 domain: analysis with monoclonal antibodies reveals distinct binding sites involved in recognition of the platelet membrane glycoprotein Ib-IX-V complex and ristocetin-dependent activation.  
Blood. 2000 Jan 1;95(1):164-72.  
PMID: 10607699 [PubMed - indexed for MEDLINE]
- ☐ **11:** [Shin Y, Morita T.](#) Related Articles, Links  
 Rhodocytin, a functional novel platelet agonist belonging to the heterodimeric C-type lectin family, induces platelet aggregation independently of glycoprotein Ib.  
Biochem Biophys Res Commun. 1998 Apr 28;245(3):741-5.  
PMID: 9588185 [PubMed - indexed for MEDLINE]
- ☐ **12:** [Sen U, Vasudevan S, Subbarao G, McClintock RA, Celikel R, Ruggeri ZM, Varughese KI.](#) Related Articles, Links  
 Crystal structure of the von Willebrand factor modulator botrocetin.  
Biochemistry. 2001 Jan 16;40(2):345-52.  
PMID: 11148028 [PubMed - indexed for MEDLINE]
- ☐ **13:** [Hirotsu S, Mizuno H, Fukuda K, Qi MC, Matsui T, Hamako J, Morita T, Titani K.](#) Related Articles, Links  
 Crystal structure of bitiscetin, a von Willebrand factor-dependent platelet aggregation inducer.  
Biochemistry. 2001 Nov 13;40(45):13592-7.  
PMID: 11695907 [PubMed - indexed for MEDLINE]
- ☐ **14:** [Andrews RK, Harris SJ, McNally T, Berndt MC.](#) Related Articles, Links  
 Binding of purified 14-3-3 zeta signaling protein to discrete amino acid sequences within the cytoplasmic domain of the platelet membrane glycoprotein Ib-IX-V complex.  
Biochemistry. 1998 Jan 13;37(2):638-47.  
PMID: 9425086 [PubMed - indexed for MEDLINE]

- ☐ **15:** [Batuwangala T, Leduc M, Gibbins JM, Bon C, Jones EY.](#) [Related Articles](#), [Links](#)  
 **Structure of the snake-venom toxin convulxin.**  
*Acta Crystallogr D Biol Crystallogr.* 2004 Jan;60(Pt 1):46-53. Epub 2003 Dec 18.  
PMID: 14684891 [PubMed - indexed for MEDLINE]
- ☐ **16:** [Taniuchi Y, Kawasaki T, Fujimura Y, Suzuki M, Titani K, Sakai Y, Kaku S, Hisamichi N, Satoh N, Takenaka T, et al.](#) [Related Articles](#), [Links](#)  
 **Flavocetin-A and -B, two high molecular mass glycoprotein Ib binding proteins with high affinity purified from Trimeresurus flavoviridis venom, inhibit platelet aggregation at high shear stress.**  
*Biochim Biophys Acta.* 1995 Jun 9;1244(2-3):331-8.  
PMID: 7599152 [PubMed - indexed for MEDLINE]
- ☐ **17:** [Ozeki Y, Matsui T, Hamako J, Suzuki M, Fujimura Y, Yoshida E, Nishida S, Titani K.](#) [Related Articles](#), [Links](#)  
 **C-type galactoside-binding lectin from Bothrops jararaca venom: comparison of its structure and function with those of botrocetin.**  
*Arch Biochem Biophys.* 1994 Jan;308(1):306-10.  
PMID: 8311467 [PubMed - indexed for MEDLINE]
- ☐ **18:** [Dong J, Schade AJ, Romo GM, Andrews RK, Gao S, McIntire LV, Lopez JA.](#) [Related Articles](#), [Links](#)  
 **Novel gain-of-function mutations of platelet glycoprotein IBalpha by valine mutagenesis in the Cys209-Cys248 disulfide loop. Functional analysis under static and dynamic conditions.**  
*J Biol Chem.* 2000 Sep 8;275(36):27663-70.  
PMID: 10837490 [PubMed - indexed for MEDLINE]
- ☐ **19:** [Baglia FA, Shrimpton CN, Emsley J, Kitagawa K, Ruggeri ZM, Lopez JA, Walsh PN.](#) [Related Articles](#), [Links](#)  
 **Factor XI interacts with the leucine-rich repeats of glycoprotein IBalpha on the activated platelet.**  
*J Biol Chem.* 2004 Nov 19;279(47):49323-9. Epub 2004 Sep 16.  
PMID: 15375170 [PubMed - indexed for MEDLINE]
- ☐ **20:** [Wang R, Kong C, Kolatkar P, Chung MC.](#) [Related Articles](#), [Links](#)  
 **A novel dimer of a C-type lectin-like heterodimer from the venom of Calloselasma rhodostoma (Malayan pit viper).**  
*FEBS Lett.* 2001 Nov 23;508(3):447-53.  
PMID: 11728470 [PubMed - indexed for MEDLINE]

Items 1 - 20 of 253

Page

1

of 13 [Next](#)[Display Summary](#)☐ Show 20☐ Sort by☐ Send to[Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)[Department of Health & Human Services](#)[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Apr 18 2005 07:10:12

## WEST Search History

[Hide Items](#)[Restore](#)[Clear](#)[Cancel](#)

DATE: Tuesday, May 03, 2005

Hide?	<u>Set</u> <u>Name</u>	<u>Query</u>	<u>Hit</u> <u>Count</u>
		<i>DB=PGPB,USPT,USOC; THES=ASSIGNEE; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L3	(glycoprotein IB binding protein   coagulation factor IX with factor X binding   GPIb) same (mutation  mutant?  substitut\$3 delet\$3 recombinant) and (inhibit\$3  antithrombot\$3)	63
<input type="checkbox"/>	L2	(glycoprotein IB binding protein   coagulation factor IX with factor X binding   GPIb) same (mutation  mutant?  substitut\$3 delet\$3 recombinant)	78
<input type="checkbox"/>	L1	(glycoprotein IB binding protein   coagulation factor IX with factor X binding ) same (mutation  mutant?  substitut\$3 delet\$3 recombinant)	0

END OF SEARCH HISTORY

## Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 63 of 63 returned.

☐ 1. Document ID: US 20050089888 A1

Using default format because multiple data bases are involved.

L3: Entry 1 of 63

File: PGPB

Apr 28, 2005

PGPUB-DOCUMENT-NUMBER: 20050089888

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20050089888 A1

TITLE: Platelet glycoprotein Ib alpha variant fusion polypeptides and methods of use thereof

PUBLICATION-DATE: April 28, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Shaw, Gray	Milton	MA	US	
Sako, Dianne	Medford	MA	US	
Kumar, Ravindra	Acton	MA	US	
Xu, Jin	Dracut	MA	US	

US-CL-CURRENT: [435/6](#); [435/199](#), [435/320.1](#), [435/325](#), [435/69.1](#), [536/23.2](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. De
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 2. Document ID: US 20050079541 A1

L3: Entry 2 of 63

File: PGPB

Apr 14, 2005

PGPUB-DOCUMENT-NUMBER: 20050079541

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20050079541 A1

TITLE: Immunoadhesin comprising a glycoprotein v1 domain

PUBLICATION-DATE: April 14, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Massberg, Steffen	Munchen		DE	
Gawaz, Meinrad	Munchen		DE	
Bultmann, Andreas	Munchen		DE	



Munch, Gotz	Munchen	DE
Ungerer, Martin	Munchen	DE
Peluso, Mario	Munchen	DE

US-CL-CURRENT: 435/7.1; 435/320.1, 435/328, 435/69.7, 530/391.1, 536/23.53

ABSTRACT:

The present invention provides a fusion protein comprising (a) the extracellular domain of glycoprotein VI or a variant thereof that is functional for binding to collagen and (b) the Fc domain of an immunoglobulin or a function-conservative part thereof, characterised by a polypeptide chain having an amino acid sequence as shown in FIG. 7 and whereby the fusion protein is obtainable by a process which provides the fusion protein in the form of a specific dimer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. D.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 3. Document ID: US 20050002865 A1

L3: Entry 3 of 63

File: PGPB

Jan 6, 2005

PGPUB-DOCUMENT-NUMBER: 20050002865

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20050002865 A1

TITLE: Diagnostic/therapeutic agents

PUBLICATION-DATE: January 6, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Klaveness, Jo	Oslo		NO	
Rongved, Pal	Oslo		NO	
Hogset, Anders	Oslo		NO	
Tolleshaug, Helge	Oslo		NO	
Cuthbertson, Alan	Oslo		NO	
Godal, Aslak	Oslo		NO	
Hoff, Lars	Oslo		NO	
Gogstad, Geir	Oslo		NO	
Bryn, Klaus	Oslo		NO	
Naevestad, Anne	Oslo		NO	
Lovhaug, Dagfinn	Oslo		NO	
Hellebust, Halldis	Oslo		NO	
Solbakken, Magne	Oslo		NO	

US-CL-CURRENT: 424/9.52

ABSTRACT:

Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound

contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWC	Draw. D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	---------

☐ 4. Document ID: US 20040229288 A1

L3: Entry 4 of 63

File: PGPB

Nov 18, 2004

PGPUB-DOCUMENT-NUMBER: 20040229288

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040229288 A1

TITLE: Substance with antithrombotic activity and method for detecting glycokallidin

PUBLICATION-DATE: November 18, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Fukuchi, Naoyuki	Kawasaki-shi		JP	
Futaki, Fumie	Kawasaki-shi		JP	
Kito, Morikazu	Kawasaki-shi		JP	
Sato, Seiichi	Kawasaki-shi		JP	
Kajiura, Takayuki	Kawasaki-shi		JP	
Ono, Yukitsugu	Kawasaki-shi		JP	
Ishii, Koichi	Kawasaki-shi		JP	
Tanaka, Akiko	Kawasaki-shi		JP	
Shinozaki, Junko	Kawasaki-shi		JP	
Jojima, Yasuko	Kawasaki-shi		JP	

US-CL-CURRENT: 435/7.1; 514/8

ABSTRACT:

A method for conveniently detecting binding between the von Willebrand factor and glycoprotein Ib and a means to be used therein. The von Willebrand factor fixed in a reactor immobilized in a reaction vessel in the presence of bptrocetin is bound to a chimeric protein constructed by fusing the carboxyl terminal of a partial protein containing the von Willebrand factor-binding site of glycoprotein Ib with the amino terminal of the Fc region of an immunoglobulin molecule. Then the Fc region of the above immunoglobulin molecule is detected to thereby detect the binding between the von Willebrand factor and the glycoprotein Ib or inhibition of this binding.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWC	Draw. D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	---------

☐ 5. Document ID: US 20040220140 A1

L3: Entry 5 of 63

File: PGPB

Nov 4, 2004

PGPUB-DOCUMENT-NUMBER: 20040220140  
PGPUB-FILING-TYPE: new  
DOCUMENT-IDENTIFIER: US 20040220140 A1

TITLE: Cell-polymer fiber compositions and uses thereof

PUBLICATION-DATE: November 4, 2004

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Vournakis, John N.	Somerville	MA	US	
Finkielsztejn, Sergio	Newton	MA	US	

US-CL-CURRENT: 514/54

## ABSTRACT:

The present invention relates to compositions comprising complexes of human cells and polymer fibers and methods of their use for therapeutic purposes. Methods of making such compositions are also provided. The present invention encompasses compositions comprising poly-.beta.-1.fwdarw.4-N-acetylglucosamine polymers and stored platelets and their use for promoting wound healing and achieving hemostasis.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	--------

☐ 6. Document ID: US 20040146851 A1

L3: Entry 6 of 63

File: PGPB

Jul 29, 2004

PGPUB-DOCUMENT-NUMBER: 20040146851  
PGPUB-FILING-TYPE: new  
DOCUMENT-IDENTIFIER: US 20040146851 A1

TITLE: Purified and isolated platelet calcium channel nucleic acids and polypeptides and therapeutic and screening methods using same

PUBLICATION-DATE: July 29, 2004

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Nichols, Timothy C.	Chapel Hill	NC	US	
Malouf, Nadia	Durham	NC	US	
Merricks, ELizabeth	Chapel Hill	NC	US	

US-CL-CURRENT: 435/4; 435/325, 435/6, 435/7.2

## ABSTRACT:

Isolated and purified platelet voltage dependent calcium channel (VDCC) .alpha..sub.1 subunit polypeptides, and nucleic acid molecules encoding the same. Recombinant host cells, recombinant nucleic acids, and recombinant proteins are also disclosed, along with methods of producing each. Isolated and purified antibodies to platelet VDCC .alpha..sub.1 subunit polypeptides, and methods of producing the same, are also disclosed. Platelet VDCC .alpha..sub.1 subunit polypeptides have biological activity in calcium transport. Thus, therapeutic and diagnostic methods involving this activity are also disclosed.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	---------

☐ 7. Document ID: US 20040141922 A1

L3: Entry 7 of 63

File: PGPB

Jul 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040141922  
PGPUB-FILING-TYPE: new  
DOCUMENT-IDENTIFIER: US 20040141922 A1

TITLE: Diagnostic/therapeutic agents

PUBLICATION-DATE: July 22, 2004

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Klaveness, Jo	Oslo		NO	
Rongved, Pal	Oslo		NO	
Hogset, Anders	Oslo		NO	
Tolleshaug, Helge	Oslo		NO	
Naevestad, Anne	Oslo		NO	
Hellebust, Halldis	Oslo		NO	
Hoff, Lars	Oslo		NO	
Cuthbertson, Alan	Oslo		NO	
Lovhaug, Dagfinn	Oslo		NO	
Solbakken, Magne	Oslo		NO	

US-CL-CURRENT: 424/9.52; 514/2

## ABSTRACT:

Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, having reporters comprising gas-filled microbubbles stabilised by monolayers of film-forming surfactants, the reporter being coupled or linked to at least one vector.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	---------

☐ 8. Document ID: US 20040087539 A1

L3: Entry 8 of 63

File: PGPB

May 6, 2004

PGPUB-DOCUMENT-NUMBER: 20040087539  
PGPUB-FILING-TYPE: new  
DOCUMENT-IDENTIFIER: US 20040087539 A1

TITLE: Method of treating conditions related to platelet activity

PUBLICATION-DATE: May 6, 2004

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Du, Xiaoping	Westmont	IL	US	

US-CL-CURRENT: 514/45; 514/263.3

## ABSTRACT:

Methods of treating thrombotic and hemostatic conditions related to platelet activity are described herein. The methods of treating thrombotic and hemostatic conditions use active agents that modulate production of guanosine 3', 5' cyclic monophosphate (cGMP) or the function of cGMP-dependent protein kinase (PKG), and its downstream effectors, the ERK and p38 pathways.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. D.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 9. Document ID: US 20040071704 A1

L3: Entry 9 of 63

File: PGPB

Apr 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040071704  
PGPUB-FILING-TYPE: new  
DOCUMENT-IDENTIFIER: US 20040071704 A1

TITLE: Antithrombotic von willebrand factor (vwf) collagen bridging blockers

PUBLICATION-DATE: April 15, 2004

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Deckmyn, Hans	Linden		BE	
Cauwenberghs, Nancy	Londerzeel		BE	
Vanhoorelbeke, Karen	Zwevegem		BE	

US-CL-CURRENT: 424/145.1; 530/388.25

## ABSTRACT:

The present invention clearly demonstrates that vWF-collagen interaction plays an important role in acute platelet-dependent arterial thrombus formation and that blockade of vWF-collagen interaction can induce complete abolition of thrombus

formation in the injured and stenosed baboon femoral arteries. Accordingly, a blocker of vWF-collagen can be used as a compound for the prevention of acute arterial thrombotic syndromes or to manufacture medicines to prevention of acute arterial thrombotic syndromes.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	---------

☐ 10. Document ID: US 20040063912 A1

L3: Entry 10 of 63

File: PGPB

Apr 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040063912

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040063912 A1

TITLE: Central airway administration for systemic delivery of therapeutics

PUBLICATION-DATE: April 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Blumberg, Richard S.	Chestnut Hill	MA	US	
Lencer, Wayne I.	Jamaica Plain	MA	US	
Simister, Neil E.	Wellesley	MA	US	
Bitonti, Alan J.	Acton	MA	US	

US-CL-CURRENT: 530/351; 530/391.1

ABSTRACT:

The present invention relates to methods and products for the transepithelial systemic delivery of therapeutics. In particular, the invention relates to methods and compositions for the systemic delivery of therapeutics by administering an aerosol containing antibodies or conjugates of a therapeutic agent with an FcRn binding partner to epithelium of central airways of the lung. The methods and products are adaptable to a wide range of therapeutic agents, including proteins and polypeptides, nucleic acids, drugs, and others. In particular embodiments the conjugates are fusion proteins in which a therapeutic polypeptide is joined at its C terminal end through a peptide linker to the N terminal end of an immunoglobulin Fc gamma heavy chain, wherein the linker includes Glycine and Serine residues and is preferably 15 amino acids long. In one embodiment the fusion protein includes an interferon-alpha 2b (IFN-.alpha.2b) joined at its C terminal end through a peptide linker having a sequence Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser (SEQ ID NO:29) to the N terminal end of a human Fc.gamma.1 heavy chain. The methods and products have the advantage of not requiring administration to the deep lung in order to effect systemic delivery.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	---------

☐ 11. Document ID: US 20040002584 A1

L3: Entry 11 of 63

File: PGPB

Jan 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040002584

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040002584 A1

TITLE: Proteins, polynucleotides encoding them and methods of using the same

PUBLICATION-DATE: January 1, 2004

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Pena, Carol E. A.	New Haven	CT	US	
Shimkets, Richard A.	Guilford	CT	US	
Li, Li	Branford	CT	US	
Shenoy, Suresh G.	Branford	CT	US	
Kekuda, Ramesh	Norwalk	CT	US	
Spytek, Kimberly A.	New Haven	CT	US	
Vernet, Corine A.M.	Branford	CT	US	
Malyankar, Uriel M.	Branford	CT	US	
Guo, Xiaojia (Sasha)	Branford	CT	US	
Gusev, Vladimir Y.	Madison	CT	US	
Casman, Stacie J.	North Haven	CT	US	
Boldog, Ferenc L.	North Haven	CT	US	
Furtak, Katarzyna	Ansonia	CT	US	
Tchernev, Velizar T.	Branford	CT	US	
Patturajan, Meera	Branford	CT	US	
Gangolli, Esha A.	Madison	CT	US	
Padigar, Muralidhara	Branford	CT	US	
Liu, Xiaohong	Branford	CT	US	
Baumgartner, Jason C.	New Haven	CT	US	
Gerlach, Valerie	Branford	CT	US	
Spaderna, Steven K.	Berlin	CT	US	
Zerhusen, Bryan D.	Branford	CT	US	

US-CL-CURRENT: 530/350

## ABSTRACT:

Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	K/MC	Draw. D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	---------

☐ 12. Document ID: US 20040002450 A1

L3: Entry 12 of 63

File: PGPB

Jan 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040002450

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040002450 A1

TITLE: Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof

PUBLICATION-DATE: January 1, 2004

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lazarovits, Janette	Reut		IL	
Hagay, Yocheved	Rehovot		IL	
Plaksin, Daniel	Rehovot		IL	
Vogel, Tikva	Rehovot		IL	
Nimrod, Abraham	Rehovot		IL	
Mar-Ham, Hagit	Aseret		IL	
Szanthon, Ester	Rehovot		IL	
Richter, Tamar	Nes Tziona		IL	
Amit, Boaz	Kiron		IL	
Cooperman, Lena	Rishon Lezion		IL	
Peretz, Tuvia	Hod Hasharon		IL	
Levanon, Avigdor	Rehovot		IL	

US-CL-CURRENT: 514/12; 514/13, 514/14, 514/15, 514/16, 530/324, 530/325, 530/326, 530/327, 530/328

## ABSTRACT:

The present invention provides epitopes present on cancer cells and important in physiological phenomena such as cell rolling, metastasis, and inflammation. Therapeutic and diagnostic methods and compositions using antibodies capable of binding to the epitopes are provided. Methods and compositions according to the present invention can be used in diagnosis of and therapy for such diseases as cancer, including tumor growth and metastasis, leukemia, auto-immune disease, and inflammatory disease

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 13. Document ID: US 20040001839 A1

L3: Entry 13 of 63

File: PGPB

Jan 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040001839

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040001839 A1



TITLE: Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof

PUBLICATION-DATE: January 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Levanon, Avigdor	Rehovot		IL	
Hagay, Yocheved	Rehovot		IL	
Plaksin, Daniel	Rehovot		IL	
Vogel, Tikva	Rehovot		IL	
Nimrod, Abraham	Rehovot		IL	
Mar-Haim, Hagit	Aseret		IL	
Szanthon, Ester	Rehovot		IL	
Richter, Tamar	Nes Tziona		IL	
Amit, Boaz	Kiron		IL	
Cooperman, Lena	Rishon Lezion		IL	
Peretz, Tuvia	Hod Hasharon		IL	
Lazarovits, Janette	Reut		IL	

US-CL-CURRENT: 424/178.1; 530/391.1

ABSTRACT:

The present invention provides epitopes present on cancer cells and important in physiological phenomena such as cell rolling, metastasis, and inflammation. Therapeutic and diagnostic methods and compositions using antibodies capable of binding to the epitopes are provided. Methods and compositions according to the present invention can be used in diagnosis of and therapy for such diseases as cancer, including tumor growth and metastasis, leukemia, auto-immune disease, and inflammatory disease

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	---------

☐ 14. Document ID: US 20040001822 A1

L3: Entry 14 of 63

File: PGPB

Jan 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040001822

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040001822 A1

TITLE: Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof

PUBLICATION-DATE: January 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Levanon, Avigdor	Rehovot		IL	

Hagay, Yocheved	Rehovot	IL
Plaksin, Daniel	Rehovot	IL
Vogel, Tikva	Rehovot	IL
Nimrod, Abraham	Rehovot	IL
Mar-Haim, Hagit	Aseret	IL
Szanthon, Esther	Rehovot	IL
Richter, Tamar	Nes Tziona	IL
Amit, Boaz	Kiron	IL
Cooperman, Lena	Rishon Lezion	IL
Peretz, Tuvia	Hod Hasharon	IL
Lazarovits, Janette	Reut	IL

US-CL-CURRENT: 424/130.1; 424/450, 424/85.4, 514/183, 514/323, 514/575, 514/59, 514/8, 530/359, 530/388.1

## ABSTRACT:

The present invention provides epitopes present on cancer cells and important in physiological phenomena such as cell rolling, metastasis, and inflammation. Therapeutic and diagnostic methods and compositions using antibodies capable of binding to the epitopes are provided. Methods and compositions according to the present invention can be used in diagnosis of and therapy for such diseases as cancer, including tumor growth and metastasis, leukemia, auto-immune disease, and inflammatory disease.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. D.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 15. Document ID: US 20030235536 A1

L3: Entry 15 of 63

File: PGPB

Dec 25, 2003

PGPUB-DOCUMENT-NUMBER: 20030235536

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030235536 A1

TITLE: Central airway administration for systemic delivery of therapeutics

PUBLICATION-DATE: December 25, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Blumberg, Richard S.	Chestnut Hill	MA	US	
Lencer, Wayne I.	Jamaica Plain	MA	US	
Simister, Neil E.	Wellesley	MA	US	
Bitonti, Alan J.	Acton	MA	US	

US-CL-CURRENT: 424/45; 424/85.5, 424/85.6, 424/85.7, 514/2, 514/44

## ABSTRACT:

The present invention relates to methods and products for the transepithelial systemic delivery of therapeutics. In particular, the invention relates to methods and compositions for the systemic delivery of therapeutics by administering an aerosol containing antibodies or conjugates of a therapeutic agent with an FcRn binding partner to epithelium of central airways of the lung. The methods and products are adaptable to a wide range of therapeutic agents, including proteins and polypeptides, nucleic acids, drugs, and others. The methods and products have the advantage of not requiring administration to the deep lung in order to effect systemic delivery.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	--------

☐ 16. Document ID: US 20030220253 A1

L3: Entry 16 of 63

File: PGPB

Nov 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030220253

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030220253 A1

TITLE: Inhibitors for use in hemostasis

PUBLICATION-DATE: November 27, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lasser, Gerald W.	Lynnwood	WA	US	
Bishop, Paul D.	Fall City	WA	US	
Fruebis, Joachim	Redmond	WA	US	
Meehan, Woerner P.	Sammamish	WA	US	

US-CL-CURRENT: 514/12

## ABSTRACT:

The present invention relates to peptide, polynucleotide and fusion proteins for use as inhibitors in hemostasis. These inhibitors are members of the family of proteins bearing a collagen-like domain and a globular domain. The inhibitors are useful for promoting blood flow in the vasculature by reducing thrombogenic and complement activity. The inhibitors are also useful for pacify collagenous surfaces and modulating wound healing.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	--------

☐ 17. Document ID: US 20030157073 A1

L3: Entry 17 of 63

File: PGPB

Aug 21, 2003

PGPUB-DOCUMENT-NUMBER: 20030157073

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030157073 A1

TITLE: Methods for pretreating a subject with apoptotic cells

PUBLICATION-DATE: August 21, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Peritt, David L.	Bala Cynwyd	PA	US	
Harriman, Gregory	Paoli	PA	US	

US-CL-CURRENT: 424/93.21; 424/93.7

## ABSTRACT:

The present invention relates to methods for treating a subject predisposed to an autoimmune disease with extracorporeal photopheresis or an effective amount of apoptotic cells before the clinical manifestation of a symptom associated with the autoimmune disease. The present invention also relates to methods for treating a subject predisposed to an atopic disease with extracorporeal photopheresis or an effective amount of apoptotic cells before the clinical manifestation of a symptom associated with the atopic disease. The present invention further relates to methods for treating a transplant donor and/or a transplant recipient, or an implant recipient with extracorporeal photopheresis or an effective amount of apoptotic cells prior to the transplant or implantation procedure.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 18. Document ID: US 20030144358 A1

L3: Entry 18 of 63

File: PGPB

Jul 31, 2003

PGPUB-DOCUMENT-NUMBER: 20030144358

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030144358 A1

TITLE: Method for inhibiting complement activation

PUBLICATION-DATE: July 31, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Pierson, Richard N. III	Nashville	TN	US	
Zorn, George L. III	Nashville	TN	US	
Giorgio, Todd D.	Nashville	TN	US	
Robson, Simon	Weston	MA	US	
Azimzadeh, Agnes M.	Brentwood	TN	US	

US-CL-CURRENT: 514/564

## ABSTRACT:

A method of inhibiting complement activation, particularly by a transplanted tissue, in a warm-blooded vertebrate. The method includes administering a therapeutically effective amount of a platelet activity modulator to a warm-blooded vertebrate before, during or after a tissue is transplanted to the warm-blooded vertebrate, whereby complement activation by the transplanted tissue is inhibited. The platelet activity modulator can include a combination of a GPIIb modulator and a GPIIb/GPIIIa modulator.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw. D.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 19. Document ID: US 20030139466 A1

L3: Entry 19 of 63

File: PGPB

Jul 24, 2003

PGPUB-DOCUMENT-NUMBER: 20030139466

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030139466 A1

TITLE: Methods for pretreating a subject with extracorporeal photopheresis

PUBLICATION-DATE: July 24, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Peritt, David L.	Bala Cynwyd	PA	US	
Harriman, Gregory	Paoli	PA	US	

US-CL-CURRENT: 514/453

## ABSTRACT:

The present invention relates to methods for treating a subject predisposed to an autoimmune disease with extracorporeal photopheresis or an effective amount of apoptotic cells before the clinical manifestation of a symptom associated with the autoimmune disease. The present invention also relates to methods for treating a subject predisposed to an atopic disease with extracorporeal photopheresis or an effective amount of apoptotic cells before the clinical manifestation of a symptom associated with the atopic disease. The present invention further relates to methods for treating a transplant donor and/or a transplant recipient, or an implant recipient with extracorporeal photopheresis or an effective amount of apoptotic cells prior to the transplant or implantation procedure.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw. D.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 20. Document ID: US 20030012789 A1

L3: Entry 20 of 63

File: PGPB

Jan 16, 2003

PGPUB-DOCUMENT-NUMBER: 20030012789

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030012789 A1

TITLE: Receptor specific transepithelial transport of therapeutics

PUBLICATION-DATE: January 16, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Blumberg, Richard S.	Chestnut Hill	MA	US	
Simister, Neil E.	Wellesley	MA	US	
Lencer, Wayne I.	Jamaica Plain	MA	US	

US-CL-CURRENT: 424/145.1; 424/155.1, 424/178.1, 424/45

ABSTRACT:

The present invention relates in general to methods and products for initiating an immune response against an antigen, and in particular relates to transepithelial delivery of antigens to provoke tolerance and immunity. The present invention further relates to methods and products for the transepithelial delivery of therapeutics. In particular, the invention relates to methods and compositions for the delivery of therapeutics conjugated to a FcRn binding partner to intestinal epithelium, mucosal epithelium and epithelium of the lung. The present invention further relates to the synthesis, preparation and use of the FcRn binding partner conjugates as, or in, pharmaceutical compositions for oral systemic delivery of drugs and vaccines.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWMC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	--------

☐ 21. Document ID: US 20020192222 A1

L3: Entry 21 of 63

File: PGPB

Dec 19, 2002

PGPUB-DOCUMENT-NUMBER: 20020192222

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020192222 A1

TITLE: Receptor specific transepithelial transport of therapeutics

PUBLICATION-DATE: December 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Blumberg, Richard S.	Chestnut Hill	MA	US	
Simister, Neil E.	Wellesley	MA	US	
Lencer, Wayne I.	Jamaica Plain	MA	US	

US-CL-CURRENT: 424/178.1; 424/155.1, 424/45

ABSTRACT:

The present invention relates in general to methods and products for initiating an immune response against an antigen, and in particular relates to transepithelial

delivery of antigens to provoke tolerance and immunity. The present invention further relates to methods and products for the transepithelial delivery of therapeutics. In particular, the invention relates to methods and compositions for the delivery of therapeutics conjugated to a FcRn binding partner to intestinal epithelium, mucosal epithelium and epithelium of the lung. The present invention further relates to the synthesis, preparation and use of the FcRn binding partner conjugates as, or in, pharmaceutical compositions for oral systemic delivery of drugs and vaccines.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. D.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

---

☐ 22. Document ID: US 20020165353 A1

L3: Entry 22 of 63

File: PGPB

Nov 7, 2002

PGPUB-DOCUMENT-NUMBER: 20020165353

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020165353 A1

TITLE: Purified and isolated platelet calcium channel nucleic acids and polypeptides and therapeutic and screening methods using same

PUBLICATION-DATE: November 7, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Malouf, Nadia	Durham	NC	US	
Nichols, Timothy C.	Chapel Hill	NC	US	

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/326, 435/69.1, 530/388.1, 536/23.5

ABSTRACT:

Isolated and purified platelet voltage dependent calcium channel (VDCC) .alpha..sub.1 subunit polypeptides, and nucleic acid molecules encoding the same. Recombinant host cells, recombinant nucleic acids and recombinant proteins are also disclosed, along with methods of producing each. Isolated and purified antibodies to platelet VDCC .alpha..sub.1 subunit polypeptides, and methods of producing the same, are also disclosed. Platelet VDCC .alpha..sub.1 subunit polypeptides have biological activity in calcium transport. Thus, therapeutic and diagnostic methods involving this activity are also disclosed.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. D.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

---

☐ 23. Document ID: US 20020123457 A1

L3: Entry 23 of 63

File: PGPB

Sep 5, 2002

PGPUB-DOCUMENT-NUMBER: 20020123457

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020123457 A1

TITLE: NOVEL ANTIPLATELET AGENT

PUBLICATION-DATE: September 5, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
LOSCALZO, JOSEPH	DOVER	MA	US	
INBAL, AIDA	HOD-HASHARON		IL	

US-CL-CURRENT: 514/2; 530/300

## ABSTRACT:

This invention combines the unique antiplatelet effects of S-nitrosothiols and the antiadhesive properties of fragments of vWF in the A1 domain to provide unique molecules that exploit both of these properties. Preferred molecules comprise a fragment of A1 (ala444-asp730) in which arginine at position 545 is replaced by cysteine (the most frequent von Willebrand disease type 2b mutation) that has been discovered to impair platelet adhesion, and to exhibit antithrombotic activity in vivo. This cysteine residue may be S-nitrosated to produce a novel molecule that has the potential for impairing platelet adhesion as well as activation/aggregation, and such molecules form the basis of a novel therapeutic method for impairing platelet responses following vascular injury or in other thrombotic disorders according to this invention.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw. D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	---------

☐ 24. Document ID: US 20020102217 A1

L3: Entry 24 of 63

File: PGPB

Aug 1, 2002

PGPUB-DOCUMENT-NUMBER: 20020102217

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020102217 A1

TITLE: Diagnostic/therapeutic agents

PUBLICATION-DATE: August 1, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Klaveness, Jo	Oslo		NO	
Rongved, Pal	Oslo		NO	
Hogset, Anders	Oslo		NO	
Tolleshaug, Helge	Oslo		NO	
Cuthbertson, Alan	Oslo		NO	
Godal, Aslak	Oslo		NO	
Hoff, Lars	Oslo		NO	
Gogstad, Geir	Oslo		NO	
Bryn, Klaus	Oslo		NO	
Naevestad, Anne	Oslo		NO	



Lovhaug, Dagfinn	Oslo	NO
Hellebust, Halldis	Oslo	NO
Solbakken, Magne	Oslo	NO

US-CL-CURRENT: 424/9.52

## ABSTRACT:

Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 25. Document ID: US 20020102215 A1

L3: Entry 25 of 63

File: PGPB

Aug 1, 2002

PGPUB-DOCUMENT-NUMBER: 20020102215

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020102215 A1

TITLE: Diagnostic/therapeutic agents

PUBLICATION-DATE: August 1, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Klaveness, Jo	Oslo		NO	
Rongved, Pal	Oslo		NO	
Hogset, Anders	Oslo		NO	
Tolleshaug, Helge	Oslo		NO	
Naevestad, Anne	Oslo		NO	
Hellebust, Halldis	Oslo		NO	
Hoff, Lars	Oslo		NO	
Cuthbertson, Alan	Oslo		NO	
Lovhaug, Dagfinn	Oslo		NO	
Solbakken, Magne	Oslo		NO	

US-CL-CURRENT: 424/9.52; 514/44

## ABSTRACT:

Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, having reporters comprising gas-filled microbubbles stabilized by monolayers of film-forming surfactants, the reporter being coupled or linked to at least one vector.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWC	Draw. Da
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 26. Document ID: US 20020019036 A1

L3: Entry 26 of 63

File: PGPB

Feb 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020019036

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020019036 A1

TITLE: Von willebrand factor derivatives and methods of isolating proteins that bind to von willebrand factor

PUBLICATION-DATE: February 14, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Schwarz, Hans-Peter	Vienna		AT	
Turecek, Peter	Klosterneuburg		AT	
Eibl, Johann	Vienna		AT	

US-CL-CURRENT: 435/174; 530/383

## ABSTRACT:

There is disclosed a vWF derivative comprised of vWF, immobilized on a carrier, which is characterized in that the vWF is r-vWF, as well as a method of isolating proteins which bind to vWF, by using this vWF derivative.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWC	Draw. Da
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 27. Document ID: US 20010046685 A1

L3: Entry 27 of 63

File: PGPB

Nov 29, 2001

PGPUB-DOCUMENT-NUMBER: 20010046685

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20010046685 A1

TITLE: Control for methods for determining platelet count and platelet function

PUBLICATION-DATE: November 29, 2001

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Moskowitz, Keith A.	San Diego	CA	US	
Manneh, Victor A.	San Diego	CA	US	
Ratnikov, Boris I.	San Diego	CA	US	

US-CL-CURRENT: 435/7.21

## ABSTRACT:

The present invention concerns a composition comprising an aqueous medium, a reagent for assessing fibrinogen biological activity and a reagent for assessing the activity of a reagent used for determining platelet count. In one particular embodiment the composition comprises an aqueous medium, an antibody for fibrinogen and fixed platelets substantially free of fibrinogen antibody binding sites. Also disclosed is a method for conducting a control for an assay for platelet function activity and a control for the platelet count assay. The method comprises utilizing a common control for the assays wherein the control does not cross-react with itself or with reagents for conducting the assays. In a particular embodiment the common control comprises an aqueous medium, a reagent for assessing fibrinogen biological activity and a reagent for binding to the reagent used for determining platelet count. Also disclosed are kits for carrying out methods in accordance with the present invention.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWOC	Draw. D.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 28. Document ID: US 6878811 B1

L3: Entry 28 of 63

File: USPT

Apr 12, 2005

US-PAT-NO: 6878811

DOCUMENT-IDENTIFIER: US 6878811 B1

TITLE: Substance with antithrombotic activity and method for detecting glycokallidin

DATE-ISSUED: April 12, 2005

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Fukuchi; Naoyuki	Kawasaki			JP
Futaki; Fumie	Kawasaki			JP
Kito; Morikazu	Kawasaki			JP
Ishii; Koichi	Kawasaki			JP
Tanaka; Akiko	Kawasaki			JP

US-CL-CURRENT: 530/387.3, 435/69.1, 435/69.6, 435/7.1, 435/7.21, 435/7.8, 435/7.92, 436/172, 436/501, 436/506, 436/507, 436/513, 436/517, 436/519, 436/520, 436/544, 436/545, 436/546, 530/383, 530/385, 530/388.1, 530/388.2

## ABSTRACT:

A method for conveniently detecting binding between the von Willebrand factor and glycoprotein Ib and a means to be used therein. The von Willebrand factor fixed in a reactor immobilized in a reaction vessel in the presence of bottrocetin is bound to a chimeric protein constructed by fusing the carboxyl terminal of a partial protein containing the von Willebrand factor-binding site of glycoprotein Ib with the amino terminal of the Fc region of an immunoglobulin molecule. Then the Fc region of the above immunoglobulin molecule is detected to thereby detect the

binding between the von Willebrand factor and the glycoprotein Ib or inhibition of this binding.

14 Claims, 12 Drawing figures  
Exemplary Claim Number: 7  
Number of Drawing Sheets: 8

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. D.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 29. Document ID: US 6850497 B1

L3: Entry 29 of 63

File: USPT

Feb 1, 2005

US-PAT-NO: 6850497  
DOCUMENT-IDENTIFIER: US 6850497 B1

TITLE: Satellite trunked radio service system

DATE-ISSUED: February 1, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sigler; C. Edward	Myersville	MD		
Sweet; Richard S.	San Diego	CA		
Skerry; Brian	Chandler	AZ		
Davies; George	White Rock			CA
Bossler; Dan	Osgoode			CA
Jones; John W.	Ontario			CA

US-CL-CURRENT: 370/310

ABSTRACT:

In a mobile satellite system, a system for providing satellite communication between multiple users in a closed user group arrangement includes first and second mobile earth terminals (METs) responsively connector to and registering with the mobile satellite system. The first MET selects a closed user group network identifier (NET. ID) representing a NET group including the first and second METs to establish voice communication therewith and transmits the NET ID to a central controller. The central controller receives the NET ID from the first MET, validates the first MET for communication, validates the NET ID, allocates a frequency for the NET group, and broadcasts the message to the NET group including the second MET informing the NET group of the allocated frequency and the voice communication associated therewith. The second MET tunes to the frequency in response to the message broadcast by the central controller, and the central controller assigns the first MET as current speaker for the NET group.

23 Claims, 42 Drawing figures  
Exemplary Claim Number: 1  
Number of Drawing Sheets: 31

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWC	Draw. D.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 30. Document ID: US 6680047 B2

L3: Entry 30 of 63

File: USPT

Jan 20, 2004

US-PAT-NO: 6680047

DOCUMENT-IDENTIFIER: US 6680047 B2

TITLE: Diagnostic/therapeutic agents

DATE-ISSUED: January 20, 2004

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Klaveness; Jo	Oslo			NO
Rongved; P.ang.1	Oslo			NO
H.o slashed.gset; Anders	Oslo			NO
Tolleshaug; Helge	Oslo			NO
Cuthbertson; Alan	Oslo			NO
Godal; Aslak	Oslo			NO
Hoff; Lars	Oslo			NO
Gogstad; Geir	Oslo			NO
Bryn; Klaus	Oslo			NO
N.ae buttet.vestad; Anne	Oslo			NO
L.o slashed.vhaug; Dagfinn	Oslo			NO
Hellebust; Halldis	Oslo			NO
Solbakken; Magne	Oslo			NO

US-CL-CURRENT: 424/9.52; 424/1.21, 424/450, 424/489, 424/9.32, 424/9.4

## ABSTRACT:

Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

30 Claims, 1 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWC	Draw. D.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 31. Document ID: US 6638510 B1

L3: Entry 31 of 63

File: USPT

Oct 28, 2003

US-PAT-NO: 6638510

DOCUMENT-IDENTIFIER: US 6638510 B1

**\*\* See image for Certificate of Correction \*\***

TITLE: Recombinant plasmid and a method of controlling the effects of Yersinia pestis

DATE-ISSUED: October 28, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Brubaker; Robert R.	Vermontville	MI		
Motin; Vladimir L.	E. Lansing	MI		
Smirnov; George B.	Moscow			RU

US-CL-CURRENT: 424/184.1; 424/234.1, 530/350

## ABSTRACT:

Described is a plasmid prepared by recombinant techniques which is used to prepare a vaccine against Y. pestis.

4 Claims, 7 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMNC	Draw. D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	---------

☐ 32. Document ID: US 6542739 B1

L3: Entry 32 of 63

File: USPT

Apr 1, 2003

US-PAT-NO: 6542739

DOCUMENT-IDENTIFIER: US 6542739 B1

TITLE: Priority and preemption service system for satellite related communication using central controller

DATE-ISSUED: April 1, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Garner; William B.	Laytonsville	MD		

US-CL-CURRENT: 455/427; 455/1, 455/12.1, 455/512

## ABSTRACT:

A priority and preemption method for performing a priority and preemption process includes the steps of satisfying a resource acquisition request from a reserve pool for an external system, and when the resource acquisition request cannot be satisfied from the reserve pool, requesting additional unused frequencies, and when the additional unused frequencies are not available, requesting to preempt active

calls. The method also includes the step of replenishing the power and the frequencies received from the frequency controller, the data hub and/or the independent operations controller when the frequencies are no longer needed by the priority and preemption system.

12 Claims, 42 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 42

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. D.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 33. Document ID: US 6538028 B1

L3: Entry 33 of 63

File: USPT

Mar 25, 2003

US-PAT-NO: 6538028

DOCUMENT-IDENTIFIER: US 6538028 B1

TITLE: Method for inhibiting complement activation

DATE-ISSUED: March 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Pierson, III; Richard N.	Nashville	TN		
Zorn, III; George L.	Nashville	TN		
Giorgio; Todd D.	Nashville	TN		
Robson; Simon	Weston	MA		
Azimzadeh; Agnes M.	Brentwood	TN		

US-CL-CURRENT: 514/564; 514/12, 514/21, 514/44, 514/557, 514/567, 514/570, 514/8

ABSTRACT:

A method of inhibiting complement activation, particularly by a transplanted tissue, in a warm-blooded vertebrate. The method includes administering a therapeutically effective amount of a platelet activity modulator to a warm-blooded vertebrate before, during or after a tissue is transplanted to the warm-blooded vertebrate, whereby complement activation by the transplanted tissue is inhibited. The platelet activity modulator can include a combination of a GPIb modulator and a GPIIb/GPIIIa modulator.

21 Claims, 2 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. D.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 34. Document ID: US 6489290 B2

L3: Entry 34 of 63

File: USPT

Dec 3, 2002

US-PAT-NO: 6489290

DOCUMENT-IDENTIFIER: US 6489290 B2

TITLE: Antiplatelet agent

DATE-ISSUED: December 3, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Loscalzo; Joseph	Dover	MA		
Inbal; Aida	Hod-Hasharon			IL

US-CL-CURRENT: 514/2; 435/69.6, 514/12, 514/8, 530/324, 530/345, 530/380, 530/383, 530/395

## ABSTRACT:

This invention combines the unique antiplatelet effects of S-nitrosothiols and the antiadhesive properties of fragments of von Willebrand (vWF) in the A1 domain to provide unique molecules that exploit both of these properties. Preferred molecules comprise a fragment of A1 (Ala 444-Asn 730) in which arginine at position 545 is replaced by cysteine (the most frequent von Willebrand disease type 2b mutation) that has been discovered to impair platelet adhesion, and to inhibit an antithrombotic activity in vivo. This cysteine residue may be S-nitrosated to produce a novel molecule that has the potential for impairing platelet adhesion as well as activation/aggregation, and such molecules form the basis of a novel therapeutic method for impairing platelet responses following vascular injury or in other thrombotic disorders according to this invention.

15 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	--------

☐ 35. Document ID: US 6485726 B1

L3: Entry 35 of 63

File: USPT

Nov 26, 2002

US-PAT-NO: 6485726

DOCUMENT-IDENTIFIER: US 6485726 B1

TITLE: Receptor specific transepithelial transport of therapeutics

DATE-ISSUED: November 26, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Blumberg; Richard S.	Chestnut Hill	MA		
Simister; Neil E.	Wellesley	MA		
Lencer; Wayne I.	Jamaica Plain	MA		



US-CL-CURRENT: [424/178.1](#); [424/185.1](#), [424/192.1](#), [424/193.1](#), [424/277.1](#)

ABSTRACT:

The present invention relates in general to methods and products for initiating an immune response against an antigen, and in particular relates to transepithelial delivery of antigens to provoke tolerance and immunity. The present invention further relates to methods and products for the transepithelial delivery of therapeutics. In particular, the invention relates to methods and compositions for the delivery of therapeutics conjugated to a FcRn binding partner to intestinal epithelium, mucosal epithelium and epithelium of the lung. The present invention further relates to the synthesis, preparation and use of the FcRn binding partner conjugates as, or in, pharmaceutical compositions for oral systemic delivery of drugs and vaccines.

10 Claims, 4 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. D.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 36. Document ID: US 6477370 B1

L3: Entry 36 of 63

File: USPT

Nov 5, 2002

US-PAT-NO: 6477370

DOCUMENT-IDENTIFIER: US 6477370 B1

TITLE: Satellite trunked radio service system

DATE-ISSUED: November 5, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sigler; C. Edward	Myersville	MD		
Sweet; Richard S.	San Diego	CA		

US-CL-CURRENT: [455/427](#); [455/512](#)

ABSTRACT:

In a mobile communication system, a system for providing communication between multiple users in a closed user group arrangement includes, for example, first and second mobile earth terminals (METs) registering with the mobile system. The first MET selects a closed user group network identifier (NET ID) representing a NET group to establish voice communication therewith and transmits the NET ID to a controller. The controller receives the NET ID from the first MET, validates the first MET for communication, validates the NET ID, allocates a frequency for the NET group, and broadcasts the message to the NET group informing the NET group of the allocated frequency. The second MET tunes to the frequency in response to the message broadcast by the central controller. The closed user group arrangement provides security measures to ensure only authorized METs gain access to the NET group, dual standby mode of operation, and/or priority default operation.

32 Claims, 62 Drawing figures  
Exemplary Claim Number: 1  
Number of Drawing Sheets: 51

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw. D.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 37. Document ID: US 6387366 B1

L3: Entry 37 of 63

File: USPT

May 14, 2002

US-PAT-NO: 6387366  
DOCUMENT-IDENTIFIER: US 6387366 B1

TITLE: Methods for reducing adverse side effects associated with cellular transplantation

DATE-ISSUED: May 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hurwitz; David R.	Boston	MA		
Cherington; Van	Harvard	MA		
Galanopoulos; Theofanis	Arlington	MA		
Levine; Peter H.	Worcester	MA		
Greenberger; Joel S.	Sewickley	PA		

US-CL-CURRENT: 424/93.1; 424/130.1, 424/93.2, 424/93.21, 435/325, 514/44

ABSTRACT:

The methods of the present invention are based on the discovery that adverse side effects (such as hemorrhage) can occur upon infusion of cells that express tissue factor. Accordingly, the methods of the invention are aimed at reducing the biological activity of tissue factor (TF) in a patient, and can be carried out by, for example: infusing fewer cells (or infuse the same number of BMSCs over a longer period of time); reducing the expression or activity of TF (within the infused cells specifically (e.g., by contacting the cells with a TF antagonist in vitro) or within the patient generally (e.g., by administering a TF antagonist to the patient); hampering the interaction of TF with factor VII(a); inhibiting the activity of the TF-factor VII(a) complex once it has formed; or inhibiting the coagulation cascade at any point downstream from formation of the complex (including inhibition of platelet activation).

12 Claims, 8 Drawing figures.  
Exemplary Claim Number: 1  
Number of Drawing Sheets: 8

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw. D.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 38. Document ID: US 6331289 B1

L3: Entry 38 of 63

File: USPT

Dec 18, 2001

US-PAT-NO: 6331289

DOCUMENT-IDENTIFIER: US 6331289 B1

TITLE: Targeted diagnostic/therapeutic agents having more than one different vectors

DATE-ISSUED: December 18, 2001

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Klaveness; Jo	Olso			NO
Rongved; P.ang.l	Olso			NO
H.o slashed.gset; Anders	Olso			NO
Tolleshaug; Helge	Olso			NO
Cuthbertson; Alan	Olso			NO
Hoff; Lars	Olso			NO
Bryn; Klaus	Olso			NO
Hellebust; Halldis	Olso			NO
Solbakken; Magne	Olso			NO

US-CL-CURRENT: 424/9.52; 424/1.21, 424/450, 424/9.4, 424/9.6

## ABSTRACT:

Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

22 Claims, 1 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 39. Document ID: US 6264917 B1

L3: Entry 39 of 63

File: USPT

Jul 24, 2001

US-PAT-NO: 6264917

DOCUMENT-IDENTIFIER: US 6264917 B1

TITLE: Targeted ultrasound contrast agents

DATE-ISSUED: July 24, 2001

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
------	------	-------	----------	---------

Klaveness; Jo	Oslo	NO
Rongved; P.ang.1	Oslo	NO
L.o slashed.vhaug; Dagfinn	Oslo	NO

US-CL-CURRENT: 424/9.52; 600/458

## ABSTRACT:

Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, having reporters comprising gas-filled microbubbles stabilised by monolayers of film-forming surfactants, the reporter being coupled or linked to at least one vector.

17 Claims, 2 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw. D.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 40. Document ID: US 6261537 B1

L3: Entry 40 of 63

File: USPT

Jul 17, 2001

US-PAT-NO: 6261537

DOCUMENT-IDENTIFIER: US 6261537 B1

TITLE: Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors

DATE-ISSUED: July 17, 2001

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Klaveness; Jo	Oslo			NO
Rongved; P.ang.1	Oslo			NO
H.o slashed.gset; Anders	Oslo			NO
Tolleshaug; Helge	Oslo			NO
N.ae butted.vestad; Anne	Oslo			NO
Hellebust; Halldis	Oslo			NO
Hoff; Lars	Oslo			NO
Cuthbertson; Alan	Oslo			NO
L.o slashed.vhaug; Dagfinn	Oslo			NO
Solbakken; Magne	Oslo			NO

US-CL-CURRENT: 424/9.52; 424/1.29, 424/489, 424/9.32, 424/9.4, 424/9.6

## ABSTRACT:

Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, having reporters comprising gas-filled microbubbles stabilised by monolayers of film-forming surfactants, the reporter being coupled or linked to at

least one vector.

22 Claims, 2 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. D.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 41. Document ID: US 6177059 B1

L3: Entry 41 of 63

File: USPT

Jan 23, 2001

US-PAT-NO: 6177059

DOCUMENT-IDENTIFIER: US 6177059 B1

**\*\* See image for Certificate of Correction \*\***

TITLE: GPIIb-lipid complex and uses thereof

DATE-ISSUED: January 23, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Matsuda; Hiroshi	Osaka			JP
Kamide; Kaeko	Hirakata			JP
Amatsuji; Yasuo	Hirakata			JP
Imagawa; Takashi	Fukuoka			JP
Ikeda; Yasuo	Tokyo			JP
Murata; Mitsuru	Niiza			JP

US-CL-CURRENT: 424/1.21; 424/9.321, 424/9.34, 424/9.37, 424/9.5, 424/9.51, 424/9.6, 514/21, 514/7, 514/8, 530/352, 530/359, 530/381, 530/395, 530/410

ABSTRACT:

A complex comprising a lipid and a conjugate of GPIIb and lipid having a functional group, and use thereof. The GPIIb-lipid complex of the present invention is extremely useful as a platelet substitute, a pharmaceutical agent for the prophylaxis and treatment of angiopathy, vascular damages and thrombosis, a diagnostic for vWF deficiency and the like, a biological or medical reagent, a reagent for screening platelet aggregation suppressant or antithrombosis, and the like. The GPIIb-lipid complex of the present invention is also useful as a diagnostic for finding the location of vascular lesion or thrombus formation, or a therapeutic agent therefor, since it accumulates at vascular lesions.

27 Claims, 0 Drawing figures

Exemplary Claim Number: 11

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. D.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 42. Document ID: US 5900476 A

L3: Entry 42 of 63

File: USPT

May 4, 1999

US-PAT-NO: 5900476

DOCUMENT-IDENTIFIER: US 5900476 A

\*\* See image for Certificate of Correction \*\*

TITLE: Therapeutic domains of van Willebrand factor

DATE-ISSUED: May 4, 1999

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ruggeri; Zaverio M.	La Jolla	CA		
Ware; Jerry L.	Encinitas	CA		

US-CL-CURRENT: 530/380; 530/829, 536/23.5

## ABSTRACT:

A polypeptide which is capable of inhibiting binding of von Willebrand factor (vWF) to platelets and comprising an amino acid sequence that corresponds to the amino acid sequence of that fragment of mature von Willebrand factor subunit having its amino terminus at about Cys.sup.509 and its carboxy terminus at about Cys.sup.695, said polypeptide comprising optionally a second and/or a third domain, the second domain corresponding to the amino acid sequence of that fragment of mature vWF subunit having its amino terminus at about Thr.sup.450 and its carboxy terminus at about Tyr.sup.508, or a subfragment or combination of subfragments thereof, and a third domain corresponding to the amino acid sequence of that fragment of mature vWF subunit having its amino terminus at about Asp.sup.696 and its carboxy terminus at about Gly.sup.727, or a subfragment or combination of subfragments thereof; and also a process for producing said polypeptides from encoding DNA sequences, and also a method of inhibiting or treating thrombosis in a patient which comprising administering to such patient an effective amount of a therapeutic composition comprising one or more polypeptides of the invention.

11 Claims, 5 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. D.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 43. Document ID: US 5877155 A

L3: Entry 43 of 63

File: USPT

Mar 2, 1999

US-PAT-NO: 5877155

DOCUMENT-IDENTIFIER: US 5877155 A

TITLE: Mimotopes and anti-mimotopes of human platelet glycoprotein Ib/IX

DATE-ISSUED: March 2, 1999

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Miller; Jonathan L.	Syracuse	NY		
Lyle; Vicki A.	Syracuse	NY		

US-CL-CURRENT: 514/15; 424/153.1, 530/300, 530/328

## ABSTRACT:

The present invention is directed to an isolated peptide that functionally mimics a binding site for a monoclonal antibody, the monoclonal antibody recognizing an epitope within the human platelet glycoprotein Ib/IX complex. This peptide is called a mimotope. The invention also provides an isolated molecule capable of binding to the peptide, or the mimotope, which molecule can be an antibody, a second peptide, a carbohydrate, a DNA molecule, an RNA molecule, or other naturally or chemically synthesized molecules. This isolated molecule is called an anti-mimotope. Mimotopes mimicking the binding site for monoclonal antibody C-34 and SZ-2, as well as anti-mimotopes to the C-34 mimotopes, are specifically provided.

2 Claims, 14 Drawing figures

Exemplary Claim Number: 1,2

Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. D.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 44. Document ID: US 5847086 A

L3: Entry 44 of 63

File: USPT

Dec 8, 1998

US-PAT-NO: 5847086

DOCUMENT-IDENTIFIER: US 5847086 A

TITLE: Therapeutic fragments of von Willebrand factor

DATE-ISSUED: December 8, 1998

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Farb; David L.	Chalfont	PA		
Hrinda; Michael E.	Gwynedd Valley	PA		
Lee; Ted C. K.	Lansdale	PA		
Prior; Christopher P.	Wayne	PA		
Weber; David	Norristown	PA		

US-CL-CURRENT: 530/383; 435/69.1, 435/69.6, 530/402, 530/412, 530/413

## ABSTRACT:

Processes for preparing aqueous solutions of cysteine-altered von Willebrand Factor fragment which are substantially free of aggregate and capable of therapeutic use for treating thrombosis are provided. The claimed process comprises providing an aqueous solution of vWF fragment and denaturant and containing undesired

contaminants, said solution having an acidic pH; separating said contaminants from said solution by contacting said solution with an affinity chromatography medium to which said vWF fragments adhere; eluting said vWF fragment from said affinity chromatography medium in the presence of the denaturant; and separating the eluted fragment from said denaturant while maintaining the aqueous solution of the fragment at a pH of about 2.5 to less than about 5.5 to increase monomerization of, and decrease aggregation of, said fragment, thereby forming an aqueous solution of vWF fragment which is substantially free of aggregate.

28 Claims, 4 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. D.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 45. Document ID: US 5817748 A

L3: Entry 45 of 63

File: USPT

Oct 6, 1998

US-PAT-NO: 5817748

DOCUMENT-IDENTIFIER: US 5817748 A

TITLE: Mimotopes of human Platelet glycoprotein Ib/IX

DATE-ISSUED: October 6, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Miller; Jonathan L.	Syracuse	NY		
Lyle; Vicki A.	Syracuse	NY		

US-CL-CURRENT: 530/300; 424/185.1, 530/326, 530/327, 530/328, 530/380

ABSTRACT:

The present invention is directed to an isolated peptide that functionally mimics a binding site for a monoclonal antibody, the monoclonal antibody recognizing an epitope within the human glycoprotein Ib/IX complex. This peptide is called a mimotope. The invention also provides an isolated molecule capable of binding to the peptide, or the mimotope, which molecule can be an antibody, a second peptide, a carbohydrate, a DNA molecule, an RNA molecule, or other naturally or chemically synthesized molecules. This isolated molecule is called an anti-mimotope. Mimotopes mimicking the binding site for monoclonal antibody C-34 are specifically provided.

1 Claims, 7 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. D.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------



☐ 46. Document ID: US 5795569 A

L3: Entry 46 of 63

File: USPT

Aug 18, 1998

US-PAT-NO: 5795569

DOCUMENT-IDENTIFIER: US 5795569 A

**\*\* See image for Certificate of Correction \*\***

TITLE: Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation

DATE-ISSUED: August 18, 1998

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bartley; Timothy D.	Thousand Oaks	CA		
Bogenberger; Jakob M.	Camarillo	CA		
Bosselman; Robert A.	Thousand Oaks	CA		
Hunt; Pamela	Thousand Oaks	CA		
Kinstler; Olaf B.	Oxnard	CA		
Samal; Babru B.	Moorpark	CA		

US-CL-CURRENT: 424/85.1; 435/69.5, 530/351, 530/402, 930/140

## ABSTRACT:

Disclosed are novel proteins, referred to as megakaryocyte growth and development factors (MGDFs; also generally referred to as Mpl ligands or thrombopoietin, that have a biological activity of stimulating the growth of megakaryocytes and augmenting the differentiation or maturation of megakaryocytes, ultimately to result in the production of platelets. MGDF derivatives comprising MGDF molecules attached to water soluble polymers, such as polyethylene glycol, are also disclosed, along with methods for their preparation. Also disclosed are processes for obtaining the MGDFs in homogeneous form from natural sources and producing them by recombinant genetic engineering techniques from mammals, including humans.

11 Claims, 25 Drawing figures

Exemplary Claim Number: 1,9

Number of Drawing Sheets: 22

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. D.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 47. Document ID: US 5766581 A

L3: Entry 47 of 63

File: USPT

Jun 16, 1998

US-PAT-NO: 5766581

DOCUMENT-IDENTIFIER: US 5766581 A

**\*\* See image for Certificate of Correction \*\***

TITLE: Method for treating mammals with monopegylated proteins that stimulates megakaryocyte growth and differentiation

DATE-ISSUED: June 16, 1998

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bartley; Timothy D.	Thousand Oaks	CA		
Bogenberger; Jakob M.	Camarillo	CA		
Bosselman; Robert A.	Thousand Oaks	CA		
Hunt; Pamela	Thousand Oaks	CA		
Kinstler; Olaf B.	Thousand Oaks	CA		
Samal; Babru B.	Moorpark	CA		

US-CL-CURRENT: 424/85.1; 435/69.5, 530/351, 530/402, 930/140

## ABSTRACT:

Disclosed are novel proteins, referred to as megakaryocyte growth and development factors (MGDFs; also generally referred to as Mpl ligands), that have a biological activity of stimulating the growth of megakaryocytes and augmenting the differentiation or maturation of megakaryocytes, ultimately to result in the production of platelets. MGDF derivatives comprising MGDF molecules attached to water soluble polymers, such as polyethylene glycol, are also disclosed, along with methods for their preparation. The MGDF proteins and derivatives are useful in methods for treating mammals to increase platelets and/or megakaryocytes. Also disclosed are processes for obtaining the MGDFs in homogeneous form from natural sources and producing them by recombinant genetic engineering techniques from mammals, including humans.

6 Claims, 29 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 29

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMCD	Draw. D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	---------

☐ 48. Document ID: US 5624817 A

L3: Entry 48 of 63

File: USPT

Apr 29, 1997

US-PAT-NO: 5624817

DOCUMENT-IDENTIFIER: US 5624817 A

TITLE: Mutations in the gene encoding the alpha chain of platelet glycoprotein Ib

DATE-ISSUED: April 29, 1997

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Miller; Jonathan L.	Syracuse	NY		
Cunningham; David	Syracuse	NY		
Lyle; Vicki A.	Syracuse	NY		
Finch; Clara N.	Webster	NY		
Pincus; Matthew R.	Syracuse	NY		

US-CL-CURRENT: [435/69.1](#); [435/252.3](#), [435/252.33](#), [435/320.1](#), [435/348](#), [435/361](#), [435/6](#),  
[435/69.6](#), [435/69.8](#), [435/70.1](#), [435/70.3](#), [536/23.1](#), [536/23.5](#), [536/24.31](#)

## ABSTRACT:

The subject invention provides purified polypeptides encoded by naturally-occurring wild-type platelet glycoprotein Ib alpha having a mutation which renders the polypeptide more reactive with von Willebrand factor. Preferably, the mutation is in the hinge region of GP Ib.alpha., such as the substitution of valine for glycine at residue 233. These mutations alter the three-dimensional structure of the mutant polypeptide from a beta bend conformation to an alpha helix formation, and also create an amphipathic region within the mutant polypeptide. DNA encoding the mutant polypeptides, as well as expression systems for the production of the mutant polypeptides, are also provided. Methods and compositions using the mutant polypeptides and DNA oligomers complementary to the mutant polypeptides are further provided.

61 Claims, 7 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	---------

☐ 49. Document ID: US 5609749 A

L3: Entry 49 of 63

File: USPT

Mar 11, 1997

US-PAT-NO: 5609749

DOCUMENT-IDENTIFIER: US 5609749 A

TITLE: Electrochemical assay method with novel p-phenylenediamine compound

DATE-ISSUED: March 11, 1997

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Yamauchi; Tadakazu	Saitama			JP
Terasawa; Hideyuki	Saitama			JP

US-CL-CURRENT: [205/777.5](#); [204/418](#), [435/817](#), [436/806](#)

## ABSTRACT:

An enzyme electrode, specific binding or the like electrochemical assay method capable of performing always stably high detection sensitivity (responsibility) and reappearance even in the case of blood, urine and the like samples that contain interfering substances and also of applying suitably to disposable use, and a novel p-phenylenediamine compound which is used in the assay method. Particularly, an electrochemical assay method in which a substance in a liquid sample is assayed using at least one oxidoreductase, wherein an oxidoreductase, an electron mediator and an electrode which performs electron transfer with the mediator are arranged in the assay system, and a compound of the following formula [I] or a salt thereof is used as the mediator which is highly soluble in water, dried (by freeze-, vacuum- or air-drying) easily and stable under dry condition, shows a high electron

transfer rate with enzymes and is almost free from the influence of interfering substances in blood, urine and the like samples: ##STR1## wherein R.sup.1 to R.sup.4 may be the same or different from one another and each means a hydrogen, a straight- or branched-chain alkyl group having 1 to 4 carbon atoms, optionally having a substituent, providing that at least one of R.sup.1 to R.sup.4 has one or more groups selected from hydroxyl, mercapto, carboxyl, phosphonooxy and sulfo.

13 Claims, 48 Drawing figures  
Exemplary Claim Number: 1  
Number of Drawing Sheets: 47

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. De
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 50. Document ID: US 5602655 A

L3: Entry 50 of 63

File: USPT

Feb 11, 1997

US-PAT-NO: 5602655

DOCUMENT-IDENTIFIER: US 5602655 A

**\*\* See image for Certificate of Correction \*\***

TITLE: Image forming system for single bit image data

DATE-ISSUED: February 11, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Arakawa; Naoto	Kawasaki			JP
Sakai; Masanori	Yokohama			JP
Kadowaki; Toshihiro	Kawasaki			JP
Ohnishi; Tetsuya	Yokohama			JP
Honma; Toshio	Kawasaki			JP

US-CL-CURRENT: 358/501; 358/521, 358/524, 358/530

ABSTRACT:

An image forming apparatus and an electronic device for outputting data to the image forming apparatus. The image forming apparatus comprises an interface for inputting single bit image data and a command from an external device, a first store for storing the single bit image data, a second store for receiving and storing color data for coloring the single bit image data, and an image forming device for forming a color image on the basis of the data in the first and second stores. The electronic device includes a first output for outputting single bit image data, a second output for outputting a color number for one pixel of color image data, and a third output for outputting both first multi-level color component data for the single bit image data and second multi-level color component data for the color number.

15 Claims, 174 Drawing figures  
Exemplary Claim Number: 1  
Number of Drawing Sheets: 123

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	---------

☐ 51. Document ID: US 5593959 A

L3: Entry 51 of 63

File: USPT

Jan 14, 1997

US-PAT-NO: 5593959

DOCUMENT-IDENTIFIER: US 5593959 A

TITLE: Mutations in the gene encoding the alpha chain of platelet glycoprotein Ib

DATE-ISSUED: January 14, 1997

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Miller; Jonathan L.	Syracuse	NY		
Cunningham; David	Syracuse	NY		
Lyle; Vicki A.	Syracuse	NY		
Finch; Clara N.	Webster	NY		
Pincus; Matthew R.	Syracuse	NY		

US-CL-CURRENT: 514/8; 128/899, 424/94.63, 424/94.64, 530/380, 530/395

## ABSTRACT:

The subject invention provides purified polypeptides encoded by naturally-occurring wild-type platelet glycoprotein Ib alpha having a mutation which renders the polypeptide more reactive with von Willebrand factor. Preferably, the mutation is in the hinge region of GP Ib.alpha., such as the substitution of valine for glycine at residue 233. These mutations alter the three-dimensional structure of the mutant polypeptide from a beta bend conformation to an alpha helix formation, and also create an amphipathic region within the mutant polypeptide. DNA encoding the mutant polypeptides, as well as expression systems for the production of the mutant polypeptides, are also provided. Methods and compositions using the mutant polypeptides and DNA oligomers complementary to the mutant polypeptides are further provided.

17 Claims, 7 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	---------

☐ 52. Document ID: US 5539086 A

L3: Entry 52 of 63

File: USPT

Jul 23, 1996

US-PAT-NO: 5539086

DOCUMENT-IDENTIFIER: US 5539086 A

TITLE: Therapeutic fragments of von Willebrand factor

DATE-ISSUED: July 23, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Farb; David L.	Chalfont	PA		
Hrinda; Michael E.	Gwynedd Valley	PA		
Lee; Ted C. K.	Lansdale	PA		
Prior; Christopher P.	Wayne	PA		

US-CL-CURRENT: 530/383; 530/408, 530/412

ABSTRACT:

An aqueous solution of cysteine-altered von Willebrand Factor fragment which is substantially free of aggregate and capable of therapeutic use for treating thrombosis and a process for preparing such a solution comprising:

(A) providing an aqueous solution of the fragment and denaturant;

(B) purifying the solution of fragment and denaturant under conditions which promote conversion of aggregated forms of the fragment to the dimeric and/or monomeric forms thereof to provide purified fragment;

(C) separating the dissolved, purified fragment from the denaturant while maintaining the aqueous solution of the fragment at a pH of about 2.5 to less than about 5.5 to increase monomerization of, and decrease aggregation of, said purified fragment, thereby forming an aqueous solution of fragment which is substantially free of aggregate.

18 Claims, 4 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	------------

☐ 53. Document ID: US 5524281 A

L3: Entry 53 of 63

File: USPT

Jun 4, 1996

US-PAT-NO: 5524281

DOCUMENT-IDENTIFIER: US 5524281 A

**\*\* See image for Certificate of Correction \*\***

TITLE: Apparatus and method for measuring the phase and magnitude of microwave signals

DATE-ISSUED: June 4, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
------	------	-------	----------	---------

Bradley; Donald A.	Morgan Hill	CA
Grace; Martin I.	San Jose	CA
Thornton; Douglas R.	Felton	CA
Finch; David P.	Morgan Hill	CA

US-CL-CURRENT: 455/67.15; 324/601

## ABSTRACT:

A measurement system is provided which comprises: source circuit for receiving feedback signals and for providing respective signals at respective discrete frequencies in a prescribed microwave frequency range, wherein the respective provided signals at respective discrete frequencies are substantially phase locked to at least one downconverted signal in response to the feedback signals; downconverting circuit for linearly downconverting the respective provided signals and for providing the at least one respective downconverted signal; and phase detector circuit for receiving the at least one respective downconverted signal and for providing the feedback signals.

50 Claims, 115 Drawing figures

Exemplary Claim Number: 42

Number of Drawing Sheets: 89

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. D.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 54. Document ID: US 5492809 A

L3: Entry 54 of 63

File: USPT

Feb 20, 1996

US-PAT-NO: 5492809

DOCUMENT-IDENTIFIER: US 5492809 A

TITLE: Mutations rendering platelet glycoprotein Ib-.alpha. less reactive

DATE-ISSUED: February 20, 1996

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Miller; Jonathan L.	Syracuse	NY		
Cunningham; David	Syracuse	NY		
Lyle; Vicki A.	Syracuse	NY		
Finch; Clara N.	Webster	NY		

US-CL-CURRENT: 435/6; 435/252.3, 435/252.33, 435/348, 435/69.1, 435/69.6, 435/70.1, 435/71.1, 435/71.2, 436/63, 536/23.1, 536/23.5, 536/24.31

## ABSTRACT:

The subject invention provides purified polypeptides encoded by naturally-occurring wild-type platelet glycoprotein Ib alpha having a mutation which renders the polypeptide less reactive with von Willebrand factor. Preferably, the mutation is in the leucine rich region of GPIb.alpha., such as the substitution of

phenylalanine for leucine at residue 57. DNA encoding the mutant polypeptides, as well as expression systems for the production of the mutant polypeptides, are also provided. Methods and compositions using the mutant polypeptides and DNA oligomers complementary to the mutant polypeptides are further provided.

22 Claims, 9 Drawing figures  
Exemplary Claim Number: 1  
Number of Drawing Sheets: 6

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMIC	Draw. D.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 55. Document ID: US 5487169 A

L3: Entry 55 of 63

File: USPT

Jan 23, 1996

US-PAT-NO: 5487169

DOCUMENT-IDENTIFIER: US 5487169 A

**\*\* See image for Certificate of Correction \*\***

TITLE: Method for translating a test plan source file containing multiple programming languages

DATE-ISSUED: January 23, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Vraney; Lawrence E.	Cary	IL		
Protofanousis; Michael S.	Glenview	IL		
Loew; Dean R.	Racine	WI		
van Daal; Robert W.	Glenview	IL		

US-CL-CURRENT: 717/142; 717/117, 717/139

ABSTRACT:

A method and apparatus for translating a text file to an executable procedure is provided. The executable procedure is created by inputting the text file to a translator, determining which translation rule to apply to the text file based upon the context within the text file, and applying the translation rule to the text file.

8 Claims, 4 Drawing figures  
Exemplary Claim Number: 1  
Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMIC	Draw. D.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 56. Document ID: US 5340727 A

L3: Entry 56 of 63

File: USPT

Aug 23, 1994



US-PAT-NO: 5340727  
DOCUMENT-IDENTIFIER: US 5340727 A

TITLE: GPIb.alpha. fragments and recombinant DNA expression vectors

DATE-ISSUED: August 23, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ruggeri; Zaverio M.	La Jolla	CA		
Ware; Jerry L.	Encinitas	CA		

US-CL-CURRENT: 435/69.6; 435/320.1, 435/360, 435/466, 435/69.8, 435/70.3, 514/8,  
514/822, 530/381, 536/23.5

ABSTRACT:

Recombinant DNA expression vectors encoding a peptide which inhibits binding of von Willebrand factor to platelet membrane glycoprotein Ib, said vector including a nucleotide sequence encoding the amino acid sequence from HIS.sup.1 to LEU.sup.610, inclusive, of the amino terminal region of platelet membrane glycoprotein Ib.alpha., or any sequential subset thereof; mammalian host cells transformed by said vectors; and a process for producing a peptide having the identifying characteristics of the 45 kDa tryptic fragment of glycocalicin comprising the steps of (A) providing a stable, extrachromosomally replicable vector capable of directing in mammalian cells the expression of a nucleotide sequence encoding an amino acid sequence which includes said fragment, said nucleotide sequence further encoding as part of said amino acid sequence amino acids which are not native to said fragment, and which are oriented at the carboxy terminus of said fragment, (B) transforming said mammalian cells with said vector, and (C) maintaining said transformed mammalian cells under conditions permitting the expression of said peptide.

19 Claims, 18 Drawing figures  
Exemplary Claim Number: 3  
Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. D.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 57. Document ID: US 5336667 A

L3: Entry 57 of 63

File: USPT

Aug 9, 1994

US-PAT-NO: 5336667  
DOCUMENT-IDENTIFIER: US 5336667 A

TITLE: Method for inhibiting the adhesion of platelet with alboaggregins: platelet agonists which bind to platelet membrane glycoprotein IB

DATE-ISSUED: August 9, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
------	------	-------	----------	---------

Kirby; Edward P. Philadelphia PA  
Peng; Man-ling Bensalem PA

US-CL-CURRENT: 514/12; 435/6, 514/2, 514/8, 530/350, 536/23.5

ABSTRACT:

A family of proteins are provided which may be purified from snake venom. Each protein binds to the 45 kDa N-terminal domain of human platelet glycoprotein Ib, thereby inhibiting the binding of Von Willebrand factor to the domain. The proteins exist as multimers of individual polypeptide chains. The single polypeptide chains are useful for inhibiting the adhesion of platelets to subendothelial components of blood vessel walls exposed as the result of vascular damage.

32 Claims, 8 Drawing figures  
Exemplary Claim Number: 1  
Number of Drawing Sheets: 8

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. D.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 58. Document ID: US 5328840 A

L3: Entry 58 of 63

File: USPT

Jul 12, 1994

US-PAT-NO: 5328840

DOCUMENT-IDENTIFIER: US 5328840 A

TITLE: Method for preparing targeted carrier erythrocytes

DATE-ISSUED: July 12, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Coller; Barry S.	Dix Hills	NY		

US-CL-CURRENT: 435/7.25; 435/180, 435/181, 435/70.21, 514/2, 530/300, 530/350

ABSTRACT:

The present invention provides new compounds and methods for promoting platelet aggregation, and controlling bleeding. The present invention is based on the surprising discovery that erythrocytes conjugated to certain peptides and polypeptides containing an R-G-D (Arg-Gly-Asp) sequence (collectively termed herein "RGD peptides") according to the invention, selectively bind to activated platelets but not to unactivated platelets. In recognition of the dual nature of the derivatized erythrocytes, they are termed herein "thrombo-erythrocytes". The thrombo-erythrocytes have no significant change in their rheological properties. In a preferred aspect, the thrombo-erythrocytes have the majority of RGD peptide cross-linked specifically to glycophorin A and glycophorin B on the surface of the erythrocyte. In the thrombo-erythrocytes of the invention, preferably, the N-terminal Arg of the R-G-D sequence should be spaced within 9-50 Angstroms, more preferably 10-40 Angstroms, and most preferably 11-25 Angstroms, from the erythrocyte protein to which the RGD peptide is conjugated. The invention is

further directed to erythrocytes modified by replacement of their intracellular contents with a composition comprising a label or agent. Such modified erythrocytes are termed herein "carrier erythrocytes". The carrier erythrocytes have use in delivery of such labels or biologically active agents to specific tissues by conjugation to a targeting agent.

20 Claims, 22 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 23

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	--------

☐ 59. Document ID: US 5321127 A

L3: Entry 59 of 63

File: USPT

Jun 14, 1994

US-PAT-NO: 5321127

DOCUMENT-IDENTIFIER: US 5321127 A

TITLE: Antiplatelet and antithrombotic activity of platelet glycoprotein Ib receptor fragments

DATE-ISSUED: June 14, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Handin; Robert	Needham	MA		

US-CL-CURRENT: 530/383; 435/69.6, 436/501, 530/380, 530/413

ABSTRACT:

A platelet glycoprotein Ib receptor fragment, having antiplatelet and antithrombotic activity, useful for blocking platelet adhesion. The invention may be used in the treatment of patients who are particularly prone to thrombosis and embolism. The invention may also be used to purify von Willebrands factor.

9 Claims, 10 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 8

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	--------

☐ 60. Document ID: US 5317097 A

L3: Entry 60 of 63

File: USPT

May 31, 1994

US-PAT-NO: 5317097

DOCUMENT-IDENTIFIER: US 5317097 A

**\*\* See image for Certificate of Correction \*\***

TITLE: Mutations in the gene encoding the .alpha. chain on platelet glycoprotein IB

DATE-ISSUED: May 31, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Miller; Jonathan L.	Syracuse	NY		
Cunningham; David	Syracuse	NY		
Lyle; Vicki A.	Syracuse	NY		
Finch; Clara N.	Webster	NY		

US-CL-CURRENT: 536/24.31; 435/252.3, 435/252.33, 435/320.1, 435/6, 435/69.6,  
435/69.8, 435/70.1, 435/70.3, 436/87, 536/23.1, 536/23.5

ABSTRACT:

The subject invention provides purified polypeptides encoded by naturally-occurring wild-type platelet glycoprotein Ib alpha having a mutation which renders the polypeptide more reactive with von Willebrand factor. Preferably, the mutation is in the hinge region of GP Ib.alpha., such as the substitution of valine for glycine at residue 233. These mutations alter the three-dimensional structure of the mutant polypeptide from a beta bend conformation to an alpha helix formation, and also create an amphipathic region within the mutant polypeptide. DNA encoding the mutant polypeptides, as well as expression systems for the production of the mutant polypeptides, are also provided. Methods and compositions using the mutant polypeptides and DNA oligomers complementary to the mutant polypeptides are further provided.

6 Claims, 7 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWOC	Draw. D.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 61. Document ID: US 5298239 A

L3: Entry 61 of 63

File: USPT

Mar 29, 1994

US-PAT-NO: 5298239

DOCUMENT-IDENTIFIER: US 5298239 A

**\*\* See image for Certificate of Correction \*\***

TITLE: Mutations rendering platelet glycoprotein IB .alpha. less reactive

DATE-ISSUED: March 29, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Miller; Jonathan L.	Syracuse	NY		
Cunningham; David	Syracuse	NY		
Lyle; Vicki A.	Syracuse	NY		
Finch; Clara N.	Webster	NY		

US-CL-CURRENT: [424/94.63](#); [424/94.64](#), [435/252.3](#), [435/320.1](#), [435/6](#), [435/69.6](#), [514/8](#),  
[530/380](#), [530/381](#), [530/395](#), [536/23.5](#)

## ABSTRACT:

The subject invention provides purified polypeptide encoded by naturally-occurring wild-type platelet glycoprotein Ib alpha having a mutation which renders the polypeptide less reactive with von Willebrand factor. Preferably, the mutation is in the leucine rich region of GPIb.alpha., such as the substitution of phenylalanine for leucine at residue 57. DNA encoding the mutant polypeptides, as well as expression systems for the production of the mutant polypeptides, are also provided. Methods and compositions using the mutant polypeptides and DNA oligomers complementary to the mutant polypeptides are further provided.

8 Claims, 9 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 6

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	--------

☐ 62. Document ID: US 5238919 A

L3: Entry 62 of 63

File: USPT

Aug 24, 1993

US-PAT-NO: 5238919

DOCUMENT-IDENTIFIER: US 5238919 A

TITLE: Peptides that inhibit von Willebrand Factor binding to the platelet SPIB receptor

DATE-ISSUED: August 24, 1993

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Zimmerman; Theodore S.	La Jolla	CA		
Fujimura; Yoshihiro	Kashihara			JP
Houghten; Richard A.	Solana Beach	CA		
Ruggeri; Zaverio M.	La Jolla	CA		

US-CL-CURRENT: [514/8](#); [514/12](#), [514/13](#), [514/14](#), [514/822](#), [530/324](#), [530/325](#), [530/326](#),  
[530/383](#), [530/395](#)

## ABSTRACT:

This invention provides a peptide fragment of human von Willebrand Factor (vWF) and sub-fragment thereof isolated as enzymtic digestion products from naturally occurring human vWF, or isolated from synthetic peptide mixtures or isolated from lysates of organisms capable of producing recombinant human vWF. The fragments and sub-fragments are useful in the prevention and treatment of cardiovascular disorders by virtue of their ability to inhibit the binding of vWF to platelets, heparin and/or collagen.

28 Claims, 13 Drawing figures

Exemplary Claim Number: 1  
Number of Drawing Sheets: 11

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	--------

☐ 63. Document ID: US 5128245 A

L3: Entry 63 of 63

File: USPT

Jul '7, 1992

US-PAT-NO: 5128245  
DOCUMENT-IDENTIFIER: US 5128245 A

TITLE: Establishment, characterization and differentiation of a new megakaryocytic cell line, the dami cells

DATE-ISSUED: July 7, 1992

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Greenberg; Sheryl M.	Brighton	MA		
Handin; Robert I.	Needham	MA		

US-CL-CURRENT: 435/29; 435/372, 435/70.1, 435/70.3, 435/70.4

ABSTRACT:

A stable mutant human megakaryocytic cell line is disclosed which is useful for the study of megakaryocytopoiesis, platelet formation and production, platelet component formation, and the identification and characterization of factors which modulate megakaryocytopoiesis.

5 Claims, 20 Drawing figures  
Exemplary Claim Number: 1  
Number of Drawing Sheets: 11

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	--------

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Term	Documents
GLYCOPROTEIN	31369
GLYCOPROTEINS	20193
IB	162789
IBS	14594
BINDING	363667
BINDINGS	9473

PROTEIN	228727
PROTEINS	190606
COAGULATION	55560
COAGULATIONS	377
FACTOR	711692
((GLYCOPROTEIN IB BINDING PROTEIN   COAGULATION FACTOR IX WITH FACTOR X BINDING   GPIB) SAME (MUTATION   MUTANT?) SUBSTITUT\$3 DELET\$3 RECOMBINANT) AND (INHIBIT\$3  ANTITHROMBOT\$3)).PGPB,USPT,USOC.	63

[There are more results than shown above. Click here to view the entire set.](#)

**Display Format:** -

[Change Format](#)

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)